<doc><docmeta id="113hr842ih">
    <bill congress="113" type="hr" number="842" version="ih"/>
    <revision id="7" commit-time="2013-03-26T21:46:11+00:00" comitter="/users/favila.xml" doc="/docs/113hr842ih/7.xml" status="complete"><description>Edited via AKN</description></revision>
</docmeta><bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HFB29EFCFA4134000A45F969EBF8522C8" public-private="public">
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 842</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130226">February 26, 2013</action-date>
			<action-desc>
        <sponsor name-id="S000244">Mr. Sensenbrenner</sponsor>
			 (for himself and <cosponsor name-id="M000933">Mr. Moran</cosponsor>) introduced
			 the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To expand the research activities of the National
		  Institutes of Health with respect to functional gastrointestinal and motility
		  disorders, and for other purposes.</official-title>
	</form>
	<legis-body id="HF4CCE939F26F414E8C8269AB0CA20C53" style="OLC">
		<section id="HAD2B9D71CA02466AB488B8491E35F2AD" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Functional Gastrointestinal and
			 Motility Disorders Research Enhancement Act of
			 2013</short-title>
        </quote>.</text>
		</section>
    <section id="HB2BA56449D6B4693984D0D006E004994">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline"><cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds the following:</text>
			<paragraph id="HC29E790F377C4BBCABFD3B316C0CF245">
        <enum>(1)</enum>
        <text>Functional
			 gastrointestinal and motility disorders (FGIMDs) are chronic conditions
			 associated with increased sensitivity of the GI tract, abnormal motor
			 functioning, and brain-gut dysfunction.</text>
			</paragraph>
      <paragraph id="H56B11C722F4C48F6A2408D5DABD490A1">
        <enum>(2)</enum>
        <text>FGIMDs are
			 characterized by symptoms in the GI tract including pain or discomfort, nausea,
			 vomiting, diarrhea, constipation, incontinence, problems in the passage of food
			 or feces, or a combination of these symptoms.</text>
			</paragraph>
      <paragraph id="H54B6D28DB8CA4FEABC890E27D222DD80">
        <enum>(3)</enum>
        <text>FGIMDs include
			 conditions such as dysphagia, gastroesophageal reflux disease, dyspepsia,
			 cyclic vomiting syndrome, gastroparesis, irritable bowel syndrome (IBS),
			 Hirschsprung’s disease, chronic intestinal pseudo-obstruction, bowel
			 incontinence, and many others, which affect the esophagus, stomach,
			 gallbladder, small and large intestine, and anorectal areas of the body.</text>
			</paragraph>
      <paragraph id="HCD671DF50088492AA1B35E90A9BA9D38">
        <enum>(4)</enum>
        <text>The severity of
			 FGIMDs ranges from mildly uncomfortable to debilitating and in some cases
			 life-threatening.</text>
			</paragraph>
      <paragraph id="H060F46680E554000BCFDB282FE3CF508">
        <enum>(5)</enum>
        <text>Effective
			 treatments for the multiple symptoms of FGIMDs are lacking, and while sufferers
			 frequently use a variety of medications and therapies for symptoms, few
			 patients report satisfaction with available treatments.</text>
			</paragraph>
      <paragraph id="HFCAFA20893BA45D3AC88B4F1C5993AB0">
        <enum>(6)</enum>
        <text>Patients with
			 FGIMDs frequently suffer for years before receiving an accurate diagnosis,
			 exposing them to unnecessary and costly tests and procedures including
			 surgeries, as well as needless suffering and expense.</text>
			</paragraph>
      <paragraph id="HB56E13F4CFC54D449D6AA3E265C06F47">
        <enum>(7)</enum>
        <text>The economic
			 impact of FGIMDs is high. The annual cost in the United States for IBS alone is
			 estimated to be between $1.7 billion and $10 billion in direct medical costs
			 (excluding prescription and over-the-counter medications) and $20 billion in
			 indirect medical costs.</text>
			</paragraph>
      <paragraph id="H8B8DC464F8BF46C2A5FAF77BFA358FF2">
        <enum>(8)</enum>
        <text>FGIMDs frequently
			 take a toll on the workplace, as reflected in work absenteeism, lost
			 productivity, and lost opportunities for the individual and society.</text>
			</paragraph>
      <paragraph id="H227CC5A4F26D42C68EDF7BAB5BF290FE">
        <enum>(9)</enum>
        <text>Gastrointestinal
			 symptoms consistent with functional gastrointestinal disorders such as IBS and
			 functional dyspepsia have been recognized as a serious and disabling issue for
			 military veterans, particularly those who have been deployed.</text>
			</paragraph>
      <paragraph id="HA9883414E7ED470D87F1C693945552A3">
        <enum>(10)</enum>
        <text>FGIMDs affect
			 individuals of all ages including children, and pediatric FGIMDs can be
			 particularly serious, leading to a lifetime of painful symptoms and medical
			 expenses associated with management of chronic illness or death.</text>
			</paragraph>
      <paragraph id="H5F087C95803742E49F3DF452D012D066">
        <enum>(11)</enum>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Commission on Digestive Diseases" entity-parent-id="7529">National
			 Institutes of Health’s National Commission on Digestive Diseases</cato:entity-ref> identified
			 comprehensive research goals related to FGIMDs in its April 2009 report to
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> and the American public entitled <quote>Opportunities and Challenges
			 in Digestive Diseases Research: Recommendations of the National Commission on
			 Digestive Diseases</quote>.</text>
			</paragraph>
    </section>
    <section id="H4ED7ECC83353431BB491002DC1298CFF">
      <enum>3.</enum>
      <header>Functional
			 gastrointestinal and motility disorders research enhancement</header>
      <text display-inline="no-display-inline"><cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation"><cato:entity-ref entity-type="act" value="Public Health Service Act/t:IV/pt:B">Part B of title IV of the Public Health
			 Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/284/etseq">42 U.S.C. 284 et seq.</cato:entity-ref>)</cato:entity> is amended by adding at the end the
			 following:</text>
			<quoted-block id="H37FCF6E9459E43E19E7823ADD587C776" style="OLC">
				<section id="HF748F8BC147F462187546DC12FCCBF41">
          <enum>409K.</enum>
          <header>Functional
				gastrointestinal and motility disorders</header>
          <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of NIH</cato:entity-ref> may expand, intensify,
				and coordinate the activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref> with respect
				to functional gastrointestinal and motility disorders (in this section referred
				to as <term>FGIMDs</term>) by—</text>
					<paragraph display-inline="no-display-inline" id="HC8D26286C8AF429E82C69C7184545288">
            <enum>(1)</enum>
            <text>expanding basic
				and clinical research into FGIMDs by implementing the research recommendations
				of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Commission on Digestive Diseases" entity-parent-id="7529">National Commission on Digestive Diseases</cato:entity-ref> relating to FGIMDs;</text>
					</paragraph>
          <paragraph id="H17E9543D6BC948EEBB1ECAAC58C49F5D">
            <enum>(2)</enum>
            <text>providing support
				for the establishment of up to five centers of excellence on FGIMDs at leading
				academic medical centers throughout the country to carry out innovative basic,
				translational, and clinical research focused on FGIMDs;</text>
					</paragraph>
          <paragraph id="HBE674AB9297B41E3A6B3000FA8D4EDEB">
            <enum>(3)</enum>
            <text display-inline="yes-display-inline">exploring collaborative research
				opportunities among the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institute of Diabetes and Digestive and Kidney Diseases" entity-parent-id="7529">National Institute of Diabetes and Digestive and Kidney
				Diseases</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Office of Research on Women's Health" entity-parent-id="7529">Office of Research on Women’s Health</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Office of Rare Diseases Research" entity-parent-id="7529">Office of Rare Disease
				Research</cato:entity-ref>, and other Institutes and Centers of the National Institutes of
				Health;</text>
					</paragraph>
          <paragraph id="HFF0F818107904CA8BC6E310E7A4B01FB">
            <enum>(4)</enum>
            <text display-inline="yes-display-inline">directing the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institute of Diabetes and Digestive and Kidney Diseases" entity-parent-id="7529">National Institute of
				Diabetes and Digestive and Kidney Disease</cato:entity-ref>s to provide the necessary funding for
				continued expansion and advancement of the FGIMDs research portfolio through
				intramural and extramural research;</text>
					</paragraph>
          <paragraph id="HB7797958B4664A9EA63CBD95E8CB7715">
            <enum>(5)</enum>
            <text display-inline="yes-display-inline">directing the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institute of Diabetes and Digestive and Kidney Diseases" entity-parent-id="7529">National Institute of
				Diabetes and Digestive and Kidney Diseases</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Eunice Kennedy Shriver National Institute of Child Health and Human Development" entity-parent-id="7529">Eunice Kennedy Shriver
				National Institute of Child Health and Human Development</cato:entity-ref> to expand research
				into FGIMDs that impact children, such as Hirschsprung’s disease and cyclic
				vomiting syndrome, and maternal health, such as fecal incontinence; and</text>
					</paragraph>
          <paragraph id="HAA5F8C69C0A44DCEA2B666DEBD7A0AE3">
            <enum>(6)</enum>
            <text>exploring
				opportunities to partner with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="9700">Department of Defense</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3600">Department of
				Veterans Affairs</cato:entity-ref> to increase research and improve patient care regarding FGIMDs
				that commonly impact veterans and active duty military personnel, such as IBS
				and
				dyspepsia.</text>
					</paragraph>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="HEE4BA3C57EE04015BA4439D088B2F749">
      <enum>4.</enum>
      <header>Promoting public
			 awareness of functional gastrointestinal and motility disorders</header>
      <text display-inline="no-display-inline"><cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation"><cato:entity-ref entity-type="act" value="Public Health Service Act/t:III/pt:B">Part B of title III of the Public Health
			 Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/243/etseq">42 U.S.C. 243 et seq.</cato:entity-ref>)</cato:entity> is amended by adding at the end the
			 following:</text>
			<quoted-block id="H2DE8E8F30EEB4FCCACE0CDCF819F4162" style="OLC">
				<section id="HB2360CBDD3C5499A94FA27A06149AAA8">
          <enum>320B.</enum>
          <header>Public
				awareness of functional gastrointestinal and motility disorders</header>
          <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may engage in public awareness
				and education activities to increase understanding and recognition of
				functional gastrointestinal and motility disorders (in this section referred to
				as <term>FGIMDs</term>). Such activities may include the distribution of print,
				film, and web-based materials targeting health care providers and the public
				and prepared and disseminated in conjunction with patient organizations that
				treat FGIMDs. The information expressed through such activites should
				emphasize—</text>
					<paragraph id="H84ED04EBD5434352AEA403A2BBE4AE9E">
            <enum>(1)</enum>
            <text>basic information
				on FGIMDs, their symptoms, prevalence, and frequently co-occurring conditions;
				and</text>
					</paragraph>
          <paragraph id="H32528553159E4BC0AA0156FE62C9DCD1">
            <enum>(2)</enum>
            <text>the importance of
				early diagnosis, and prompt and accurate treatment of
				FGIMDs.</text>
					</paragraph>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H13A1A7F0ACDD425AB653220F0FC326EF">
      <enum>5.</enum>
      <header>Sense of Congress
			 on the development and oversight of innovative treatment options for functional
			 gastrointestinal and motility disorders</header>
      <text display-inline="no-display-inline">It is the sense of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> that,
			 considering the current lack of effective treatment options for the global
			 symptoms of functional gastrointestinal and motility disorders (in this section
			 referred to as <term>FGIMDs</term>) and the inherent challenges of developing
			 and bringing such treatments to market, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref>
			 should continue and accelerate important efforts to improve the development and
			 oversight of treatment options for FGIMDs by—</text>
			<paragraph id="H13F1CC71F267416FB2D657E555707344">
        <enum>(1)</enum>
        <text>enhancing the
			 commitment to emerging efforts like the Patient Reported Outcomes Consortium to
			 expedite medical device and drug development, study appropriate balances
			 between risk and patient benefit, and identify proper endpoints for conditions
			 without clear, biological indicators;</text>
			</paragraph>
      <paragraph id="HA71EED4FD5F74E9396E61D648BB2D27A">
        <enum>(2)</enum>
        <text>enhancing the
			 commitment to broad efforts like the Critical Path Initiative focused on
			 ensuring that scientific breakthroughs are quickly translated into safe and
			 beneficial treatment options; and</text>
			</paragraph>
      <paragraph id="H4BAF3E5B41DB4CDBB7DE308C904DCFBC">
        <enum>(3)</enum>
        <text display-inline="yes-display-inline">continuing collaboration with patient
			 organizations that treat FGIMDs so that the patient perspective is considered
			 when determining the need for innovative treatments.</text>
			</paragraph>
    </section>
  </legis-body>
</bill></doc>